Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Humanization by Composite Human Antibodies™

Composite Human Antibody technology generates humanized non-immunogenic antibodies by avoiding T cell epitopes (deimmunisation) in variable region (V region) sequences. Unlike other humanization technologies that use single human V region frameworks as ‘acceptors’ for complimentarity-determining regions (CDRs) from the starting antibody (typically rodent), Composite Human Antibodies™ comprise multiple sequence segments (‘composites’) derived from V regions of unrelated human antibodies. The key properties of Composite Human Antibodies are as follows:

  • Sequence segments derived from databases of unrelated human V regions are selected after determining amino acids which are considered critical for antigen binding of the starting antibody.
  • All selected sequence segments derived from human V region databases are filtered for the presence of potential T cell epitopes using Antitope’s in silico tools. Composite Human Antibodies™ retain affinity and specificity better than standard humanized antibodies due to the close fit of human sequence segments with all sections of the starting antibody V regions.
  • Composite Human Antibodies™ are depleted of T cell epitopes and therefore considered both humanized and deimmunised.